Spruce Biosciences (SPRB) – Research Analysts’ Recent Ratings Updates

Spruce Biosciences (NASDAQ: SPRB) has recently received a number of price target changes and ratings updates:

• 9/24/2026 – Spruce Biosciences had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $144.00 price target on the stock.
• 9/18/2026 – Spruce Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/17/2026 – Spruce Biosciences is now covered by Lake Street Capital. They set a “buy” rating and a $149.00 price target on the stock.
• 9/16/2026 – Spruce Biosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/27/2026 – Spruce Biosciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/26/2026 – Spruce Biosciences had its “buy” rating reaffirmed by HC Wainwright.
• 8/17/2026 – Spruce Biosciences had its “buy” rating reaffirmed by Guggenheim. They now have a $104.00 price target on the stock, down from $123.00.
• 8/15/2026 – Spruce Biosciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/13/2026 – Spruce Biosciences was upgraded by The Goldman Sachs Group, Inc. to “overweight”.
• 8/13/2026 – Spruce Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Spruce Biosciences had its price target lowered by Citizens Jmp from $150.00 to $144.00. They now have a “market outperform” rating on the stock.
• 8/12/2026 – Spruce Biosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Spruce Biosciences, Inc is a biotechnology company focused on developing medicines for rare endocrine disorders. The company’s research centers on conditions in which abnormal hormone production creates significant health complications and limited treatment options.

Spruce’s lead product candidate is tildacerfont, an investigational, orally administered selective corticotropin-releasing factor type 1 receptor antagonist. The therapy is designed to regulate the hypothalamic-pituitary-adrenal axis and reduce excessive adrenocorticotropic hormone and adrenal androgen production.